(Q34455301)

English

Prognostic and predictive value of Phospho-p44/42 and pAKT in HER2-positive locally advanced breast cancer patients treated with anthracycline-based neoadjuvant chemotherapy

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Prognostic and predictive value of Phospho-p44/42 and pAKT in HER2-positive locally advanced breast cancer patients treated with anthracycline-based neoadjuvant chemotherapy (English)

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

1 reference

based on heuristic

inferred from title

author name string

Liang Huang

1

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Tianwen Chen

2

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Canming Chen

3

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Sheng Chen

4

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Yin Liu

5

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Jiong Wu

6

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Zhiming Shao

7

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

publication date

30 November 2013

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

World Journal of Surgical Oncology

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

11

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

307

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

High ERK protein expression levels correlate with shorter survival in triple-negative breast cancer patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4220778

6 July 2018

Increased signalling of EGFR and IGF1R, and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4220778

6 July 2018

What is the current standard of care for anti-HER2 neoadjuvant therapy in breast cancer?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4220778

6 July 2018

Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4220778

6 July 2018

A robust immunohistochemical assay for detecting PTEN expression in human tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4220778

6 July 2018

Insulin-like growth factor-I activates gene transcription programs strongly associated with poor breast cancer prognosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4220778

6 July 2018

An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4220778

6 July 2018

PIK3CA-activating mutations and chemotherapy sensitivity in stage II-III breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4220778

6 July 2018

Akt and XIAP regulate the sensitivity of human uterine cancer cells to cisplatin, doxorubicin and taxol

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4220778

6 July 2018

HER2/neu in systemic therapy for women with breast cancer: a systematic review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4220778

6 July 2018

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4220778

6 July 2018

Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4220778

6 July 2018

Incorporating trastuzumab into the neoadjuvant treatment of HER2-overexpressing breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4220778

6 July 2018

Insulin-like growth factor-I receptor overexpression mediates cellular radioresistance and local breast cancer recurrence after lumpectomy and radiation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4220778

6 July 2018

CMF vs alternating CMF/EV in the adjuvant treatment of operable breast cancer. A single centre randomised clinical trial (Naples GUN-3 study).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4220778

6 July 2018

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4220778

6 July 2018

HER2 and responsiveness of breast cancer to adjuvant chemotherapy.

1 reference

https://api.crossref.org/works/10.1186%2F1477-7819-11-307

21 January 2018

Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.

1 reference

https://api.crossref.org/works/10.1186%2F1477-7819-11-307

21 January 2018

Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial.

1 reference

https://api.crossref.org/works/10.1186%2F1477-7819-11-307

21 January 2018

Expression of pERK and pAKT in pediatric high grade astrocytomas: correlation with YKL40 and prognostic significance.

1 reference

https://api.crossref.org/works/10.1186%2F1477-7819-11-307

21 January 2018

Prognostic significance of IGF-1R expression in patients treated with breast-conserving surgery and radiation therapy

1 reference

https://api.crossref.org/works/10.1186%2F1477-7819-11-307

21 January 2018

EGFR, pMAPK, pAkt and PTEN status by immunohistochemistry: correlation with clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumab.

1 reference

https://api.crossref.org/works/10.1186%2F1477-7819-11-307

21 January 2018

Activated mitogen-activated protein kinase expression during human breast tumorigenesis and breast cancer progression.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4220778

27 October 2018

erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/24289519

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/24289519

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Expression patterns and predictive value of phosphorylated AKT in early-stage breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/24289519

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lower Level of MAPK Expression Is Associated with Anthracycline Resistance and Decreased Survival in Patients with Hormone Receptor Negative Breast Cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/24289519

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/24289519

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic significance of Ki67 index after neoadjuvant chemotherapy in breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/24289519

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A prognostic model to predict outcome of patients failing to achieve pathological complete response after anthracycline-containing neoadjuvant chemotherapy for breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/24289519

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/1477-7819-11-307

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34455301&oldid=2196649410"